# Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06239194/  
OnCo record `nct06239194` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MDX2001 in biliary tract cancer, cervical cancer, colorectal cancer, endometrial cancer, oesophageal cancer and gastric & gastro-oesophageal junction cancer, run by ModeX Therapeutics, An OPKO Health Company, now recruiting.

## Summary

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06239194 by ModeX Therapeutics, An OPKO Health Company, with 285 participants planned, started 2024-06-12 and due to reach its primary completion in 2028-08. Interventions recorded: MDX2001.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06239194
- Phase: 1/2
- Setting: A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: ModeX Therapeutics, An OPKO Health Company
- Enrolled: 285

## Sources

- ClinicalTrials.gov NCT06239194: https://clinicaltrials.gov/study/NCT06239194

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)

---
JSON: https://onco.cc/api/v1/entities/nct06239194.json